IL-1b drives SARS-CoV-2 disease in vivo, independently of the inflammasome and pyroptotic signalling

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Excessive inflammation and cytokine release are hallmarks of severe COVID-19. Programmed cell death processes can drive inflammation, however, the relevance in the pathogenesis of severe COVID-19 is unclear. Pyroptosis is a pro-inflammatory form of regulated cell death initiated by inflammasomes and executed by the pore-forming protein gasdermin D (GSDMD). Using an established mouse-adapted SARS-CoV-2 virus and a combination of gene-targeted mice we found that deletion of the inflammasome (NLRP1/3 and the adaptor ASC) and pore forming proteins involved in pyroptosis (GSDMA/C/D/E) did not impact disease outcome or viral loads. Furthermore, we found that SARS-CoV-2 infection did not trigger GSDMD activation in mouse lungs. We did not observe any difference between WT animals and mice with compound deficiencies in upstream caspases C1/11/12 −/− . This indicates that the classical canonical and non-canonical pro-inflammatory caspases known to process and activate IL-1β, IL-18 and GSDMD do not substantially contribute to SARS-CoV-2 pathogenesis. However, the loss of IL-1β, but not the absence of IL-18, ameliorated disease and enhanced survival in older animals compared to wildtype mice. Collectively, these findings indicate that IL-1β is an important factor contributing to severe SARS-CoV-2 disease, but its release was largely independent of inflammasome and pyroptotic pathways.

Article activity feed